Le Lézard
Classified in: Business
Subject: ATY

MGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!


NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGenics securities between March 7, 2024, and May 9, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MGNX.

Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study. The claims arise on May 9, 2024, when MacroGenics presented interim updated safety and efficacy data for its cancer treatment study TAMARACK. When the true details entered the market, the lawsuit claims that investors suffered damages.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MGNX or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in MacroGenics you have until September 24, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC


These press releases may also interest you

at 17:41
K-Bro Linen Inc. (the "Corporation") announced today a dividend of 10.00 cents CDN per common share of the Corporation for the period from October 1 to 31, 2024, to be paid on November 15, 2024 to holders of record of common shares on October 31,...

at 17:30
Sparton Resources , ("the Company") is pleased to report that Ivanhoe Electric Inc. announced today that definitive agreements have been signed between VRB Energy Inc. ("VRB Energy"), and a subsidiary of privately held Shanxi Red Sun Co., Ltd. ("Red...

at 17:30
The Container Store Group, Inc. today announced that its second quarter fiscal 2024 financial results will be released after market close on Tuesday, October 29, 2024. The Company will host a conference call at 4:30 p.m. Eastern Time to discuss the...

at 17:30
John Baird, Chairman of Canfor Pulp Products Inc. Board of Directors announced today that Stephen Mackie has been appointed President and Chief Executive Officer of Canfor Pulp effective November 1, 2024. "With almost twenty years at Canfor and 30...

at 17:30
Ribbon Communications Inc. , a global provider of real time communications technology and IP optical networking solutions to many of the world's largest service providers, enterprises, and critical infrastructure operators to modernize and protect...

at 17:25
Cryo-Cell International, Inc. (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated...



News published on and distributed by: